Timing of follow-up densitometry in hormone replacement therapy users for optimal osteoporosis prevention

Miguel A. Checa, L. Del Rio, J. Rosales, X. Nogués, J. Vila, R. Carreras

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)


The objectives of the study were (1) to determine the time interval for repeat dual-energy X-ray absorptiometry (DXA) to detect significant bone loss, i.e., greater than the coefficient of variation (CV) of the center (2.8 × CV%) and (2) to assess how long hormone replacement therapy can be maintained to avoid undetected development of low bone mass and to not unduly delay appropriate treatment. A total of 3,826 healthy women, aged 40-65 years, participated in a prospective cohort study, 807 of whom were treated with transdermal estrogen replacement therapy and 626 with transdermal estrogen/progesterone regimens. The untreated group included the remaining 2,393 women. Between 1996 and 2002 they underwent a baseline DXA scan, and DXA scans were then repeated annually. There were no differences among the study groups at entry into the study. Treatment with estrogen was a protective factor for loss of bone mass at the lumbar spine (odds ratio [OR] =0.431, 95% confidence interval [CI] 0.344 to 0.522) and at the femoral neck (OR =0.433, 95% CI 0.352 to 0.521). Treatment with estrogen/progesterone also showed a protective effect against significant changes in follow-up BMD (>2.8 × 1.05% CV of densitometry at L1-L4, >2.8 × 2.3% CV at the femoral neck). In the treated group, significant differences in BMD at the lumbar spine (OR =1.593, 95% CI 1.423 to 2.355) did not appear within the first 3 years, and differences in BMD at the femoral neck (OR =3.555, 95% CI 2.782 to 4.905) did not appear within the first 4 years. It is concluded that in women aged 45-65 years, receiving transdermal hormone replacement therapy without risk factor for loss of bone mass, such as age < 55 years and body mass index <25 kg/m 2, periodical follow-up densitometries would not be necessary, provided that the duration of estrogen or estrogen/progesterone therapy is shorter than 3 years. © International Osteoporosis Foundation and National Osteoporosis Foundation 2004.
Original languageEnglish
Pages (from-to)937-942
JournalOsteoporosis International
Issue number8
Publication statusPublished - 1 Jul 2005


  • Bone densitometry
  • Bone mass
  • Bone mineral density
  • Dual energy X-ray absorptiometry (DXA)
  • Hormone replacement therapy
  • Menopause


Dive into the research topics of 'Timing of follow-up densitometry in hormone replacement therapy users for optimal osteoporosis prevention'. Together they form a unique fingerprint.

Cite this